Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Frontiers in Oncology

Oncology

Kalhil Zaman¹  Francois P. Duhoux²  Romano Danesi³  Henrik Lindman⁴  Dimitrios Mavroudis⁵  Christian Singer⁶  Anton Snegovoy⁷  Corrado Girmenia⁸  Ida Paris⁹  Christian Schem^1,10  Marina Elena Cazzaniga^1,11  Fabrizio Luppi^1,12  Antonio Ciaccio^1,13  Ahmed Samreen^1,14  Ayodele Olubukola^1,15 

[1] Breast Center, Department Of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland;Cliniques Universitaires Saint-Luc, UC Louvain, Brussels, Belgium;Department Experimental and Clinical Medicine, University of Pisa, Pisa, Italy;Department Of Immunology, Genetics And Pathology, Uppsala University, Uppsala, Sweden;Department Of Medical Oncology, University Hospital Of Heraklion, Crete, Greece;Department Of Obstetrics & Gynecology Head, Center For Breast Health, Medical University of Vienna, Vienna, Austria;Department Of Oncology, University Of Medicine & Dentistry, Moscow, Russia;Department of Hematology, Oncology and Dermatology, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy;Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;MaHM Mammazentrum, Hamburg, Germany;Phase 1 Research Unit, IRCCS San Gerardo dei Tintori, Monza (MB), Italy;School of Medicine and Surgery, Milano Bicocca University, Monza (MB), Italy;School of Medicine and Surgery, Milano Bicocca University, Monza (MB), Italy;Division Of Respiratory Diseases, Fondazione IRCCS San Gerardo Dei Tintori, Monza (MB), Italy;School of Medicine and Surgery, Milano Bicocca University, Monza (MB), Italy;Gastroenterologic Unit, IRCCS San Gerardo dei Tintori, Monza (MB), Italy;University Hospitals Of Leicester Osborne Building, Leicester Royal Infirmary, Leicester, United Kingdom;University Hospitals of Leicester NHS Trust, Leicester, United Kingdom;

关键词: CDK 4/6 inhibitors;    abemaciclib;    ribociclib;    palbociclib;    diarrhea;    liver toxicity and injury;    interstitial lung disease;   

DOI  :  10.3389/fonc.2023.1247270

 received in 2023-06-25, accepted in 2023-09-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient.

【 授权许可】

Unknown   
Copyright © 2023 Cazzaniga, Ciaccio, Danesi, Duhoux, Girmenia, Zaman, Lindman, Luppi, Mavroudis, Paris, Olubukola, Samreen, Schem, Singer and Snegovoy